Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic Acid effects on FXR signaling in heavy drinkers
NCT02654236Completed
- Start
- Apr 2016
- Primary completion
- Sep 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of obeticholic acid in alcohol-associated liver disease (ALD) (3 arms). Primary endpoints: Change in Bile Salt Metabolism (C4) Levels at 28 days and Change in FGF19 Levels at 28 days. Started Apr 2016; status: completed.
02
Drugs
obeticholic acid
03
Conditions
alcohol-associated liver disease (ALD)
Beyond the preview
Go deeper on NCT02654236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02654236.